Compositions and methods for treating transthyretin (TTR)-mediated amyloidosis

Abstract

Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR) inhibitor composition.

Description

[Technical field]

[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 183,434, filed May 3, 2021. The entire contents of the aforementioned application are incorporated herein by reference.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on April 29, 2022, is named 121301-20020_SL.txt, and is 1,692 bytes in size. [Background technology]

[0003] Transthyretin (TTR) is a tetrameric protein that is primarily produced in the liver. Mutations in the TTR gene destabilize the protein tetramer, leading to misfolding of monomers and aggregation into TTR amyloid fibrils (ATTR). Tissue deposition leads to systemic ATTR amyloidosis (Coutinho et al., Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner et al., Amyloid and Amyloidosis, Amsterdam: Excerpta Media, 1980 pg. 88-93; Hou et al., Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007, 274: 1637-1650; Westermark et al., Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990, 87: 2843-2845). Over 100 reported TTR mutations exhibit various disease manifestations.

[0004] TTR amyloidosis manifests in a variety of forms. When the peripheral nervous system is more prominently affected, the disease is called familial amyloid polyneuropathy (FAP). When the heart is primarily involved but not the nervous system, the disease is called familial amyloid cardiomyopathy (FAC). The third major type of TTR amyloidosis is called leptomeningeal / CNS (central nervous system) amyloidosis.

[0005] The most common mutations associated with familial amyloid polyneuropathy (FAP) and ATTR-related cardiomyopathy are Val30Met (Coelho et al., Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012,79:785-792) and Val122Ile (Connors et al., Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009,158:607-614), respectively.

[0006] Current treatment options for FAP focus on stabilizing or reducing the amount of circulating amyloidogenic proteins. Orthotopic liver transplantation reduces mutant TTR levels (Holmgren et al., Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991,40:242-246) and has been reported to improve survival in early-stage FAP patients, but wild-type TTR deposition can continue (Yazaki et al., Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs into myocardium in FAP patients. Am J Transplant 2007,7:235-242; Adams et al., Rapid progression of familial amyloid polyneuropathy: a multinational natural history study Neurology 2015 Aug 25;85(8)675-82; Yamashita et al., Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012,78:637-643;Okamoto et al.,Liver transplantation for familial amyloidotic polyneuropathy:impact on Swedish patients'survival.Liver Transpl 2009,15:1229-1235;Stangou et al.,Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy:implications for amyloid fibrillogenesis.Transplantation 1998,66:229-233;Fosby et al.,Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013.Scand J Gastroenterol.2015 Jun;50(6):797-808.Transplantation,in press)。.

[0007] Tafamidis and diflunisal can stabilize circulating TTR tetramers and slow the rate of disease progression (Berk et al., Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013,310:2658-2667; Coelho et al., 2012; Coelho et al., Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013,260:2802-2814; Lozeron et al., Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013,20:1539-1545). However, symptoms continue to worsen during treatment in the majority of patients, highlighting the need for new, disease-modifying treatment options for FAP.

[0008] Descriptions of dsRNAs targeting TTR can be found, for example, in International Patent Application No. PCT / US2009 / 061381 (WO2010 / 048228) and International Patent Application No. PCT / US2010 / 055311 (WO2011 / 056883). Summary of the Invention

[0009] Described herein are methods of treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) (with or without polyneuropathy and / or cardiomyopathy) in a human patient in need thereof, the method comprising administering to the patient a patisiran pharmaceutical agent described in Table 1A, 1B, or 1C at an siRNA dose of 0.3 mg per kg of body weight, where patisiran is administered intravenously once every three weeks, and the method results in stabilization or improvement of FAP stage, PND score, modified Neuropathy Impairment Score (mNIS+7) or other neuropathy-related clinical endpoint, serum percent TTR concentration, cardiac markers and / or echocardiographic parameters.

[0010] Also described herein is a method for reducing or stopping the increase in neuropathy impairment score (NIS) or modified NIS (mNIS+7) in a human subject in need thereof by administering an effective amount of a transthyretin (TTR) inhibitor composition, the effective amount reducing the concentration of TTR protein in the serum of the human subject by less than 50 μg / ml or at least 80%. Also described herein is a method for adjusting the dosage of a TTR inhibitor composition for the treatment of increased NIS or familial amyloid polyneuropathy (FAP) by administering a TTR inhibitor composition to a subject with increased NIS or FAP and determining the level of TTR protein in the subject with increased NIS or FAP. In some embodiments, the amount of the TTR inhibitor composition administered to the subject is then increased if the level of TTR protein is greater than 50 μg / ml, and the amount of the TTR inhibitor composition administered to the subject is then decreased if the level of TTR protein is less than 50 μg / ml. Also described herein is a formulation of siRNA that inhibits TTR.

[0011] In one aspect, the invention provides a method of treating hereditary transthyretin-mediated amyloidosis with polyneuropathy and / or cardiomyopathy (hATTR amyloidosis) in a human patient in need thereof, the method comprising administering to the patient a patisiran pharmaceutical agent described in Table 1A, 1B or 1C, wherein the method results in improvement or stabilization of cardiac function.

[0012] In some embodiments, the patisiran pharmaceutical is administered at a dose of 0.3 mg of siRNA per kg of body weight.

[0013] In some embodiments, the patisiran medication is administered intravenously once every three weeks.

[0014] In some embodiments, the method reduces the progression of left ventricular chamber dysfunction.

[0015] In some embodiments, the method prevents a reduction in left ventricular capacitance.

[0016] In some embodiments, the methods result in improvement or stabilization of cardiac markers and / or echocardiographic parameters.

[0017] In some embodiments, the echocardiographic parameter is isovolumic pressure volume (PV) area.

[0018] In some embodiments, the isovolumic PV area is indexed to a left ventricular (LV) end-diastolic pressure of 30 mmHg (PVAiso30).

[0019] In some embodiments, the change in isovolumic PV area compared to a baseline determined prior to administration of the patisiran pharmaceutical agent is stabilized compared to administration of a placebo.

[0020] In some embodiments, the change from baseline in PVAiso30 is less than 1500, less than 1200, less than 1000, less than 800, less than 600, less than 500, less than 400, less than 300, less than 200, less than 150, or less than 100 mmHg*mL after 9 months of treatment.

[0021] In some embodiments, the change from baseline in PVAiso30 is less than 2500, less than 2000, less than 1500, less than 1200, less than 1000, less than 900, less than 800, less than 700, or less than 600 mmHg*mL after 18 months of treatment.

[0022] In another aspect, the invention provides a method of treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof, the method comprising administering to the patient a patisiran pharmaceutical agent as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran pharmaceutical agent is administered intravenously once every three weeks, and the method results in stabilization or improvement of FAP stage, PND score, modified Neuropathy Impairment Score (mNIS+7) or other neuropathy-related clinical endpoint, serum percent TTR concentration, cardiac markers and / or echocardiographic parameters.

[0023] In one aspect, the invention provides a method of treating Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR Amyloidosis) in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in a reduction in modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score from baseline determined at 18 months, where the baseline is the patient's mNIS+7 score prior to administration of the patisiran medication.

[0024] In one aspect, the invention provides a method of treating hereditary transthyretin-mediated amyloidosis with cardiomyopathy (hATTR amyloidosis) in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in stabilization or improvement in serum NT-proBNP concentration and / or left ventricular (LV) strain and / or LV wall thickness compared to a baseline determined prior to administration of the patisiran medication.

[0025] In another aspect, the invention provides a method for treating Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy and Polyneuropathy (hATTR Amyloidosis) in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, the method results in a reduction in modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score from baseline determined at 18 months, the baseline being the patient's mNIS+7 score prior to administration of the patisiran medication, and the method results in stabilization or improvement in serum NT-proBNP concentration and / or left ventricular (LV) strain and / or LV wall thickness compared to the baseline determined prior to administration of the patisiran medication.

[0026] In one aspect, the invention provides a method for reducing a modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in a reduction in a modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score from baseline determined at 18 months, where the baseline is the patient's mNIS+7 score prior to administration of the patisiran medication.

[0027] In another aspect, the present invention provides a method for stabilizing or improving quality of life, mobility, disability, walking speed, nutritional status, and / or autonomic symptoms in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in stabilization or improvement of each of the quality of life, mobility, disability, walking speed, nutritional status, and / or autonomic symptoms compared to a baseline determined prior to administration of the patisiran medication.

[0028] In one aspect, the invention provides a method for stabilizing or improving at least one neuropathy related clinical endpoint selected from the group consisting of Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN), NIS-W, Rasch-built Global Disability Score (R-ODS), 10-Meter Walk Test (10-MWT), modified Body Mass Index (mBMI), and COMPASS-31 score in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in the stabilization or improvement of the at least one clinical endpoint compared to a baseline determined prior to administration of the patisiran medication.

[0029] In another aspect, the present invention provides a method for stabilizing or improving serum NT-proBNP concentration and / or left ventricular (LV) strain and / or LV wall thickness in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in stabilization or improvement of serum NT-proBNP concentration and / or left ventricular (LV) strain and / or LV wall thickness, respectively, compared to a baseline determined prior to administration of the patisiran medication.

[0030] In another aspect, the present invention provides a method for stabilizing or improving FAP stage and / or PND score and / or serum percent TTR concentration in a human patient in need thereof, the method comprising administering to the patient a patisiran medication as described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran medication is administered intravenously once every three weeks, and the method results in stabilization or improvement of the FAP stage and / or PND score and / or serum percent TTR concentration, respectively, compared to a baseline determined prior to administration of the patisiran medication.

[0031] In some embodiments, the change from baseline in the mNIS+7 score is -6.0 points.

[0032] In some embodiments, the reduction from baseline in mNIS+7 score is also determined at 9 months.

[0033] In some embodiments, the method comprises: a. Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN), and b. NIS-W, and c. Rasch-built general disability score (R-ODS), and d. 10-meter walk test (10-MWT), and e. Modified Body Mass Index (mBMI), and f. COMPASS-31 score.

[0034] In some embodiments, the method results in improvement of all neuropathy-related clinical endpoints.

[0035] In some embodiments, the methods result in improvements in Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN) and COMPASS-31 scores and the 10 meter walk test.

[0036] In some embodiments, the method results in a reduction in serum percent TTR concentration in the patient compared to a baseline determined prior to administration of the patisiran pharmaceutical agent.

[0037] In some embodiments, the methods result in stabilization or regression of FAP stage in the patient compared to a baseline determined prior to administration of the patisiran medication.

[0038] In some embodiments, the methods result in stabilization or regression of PND scores compared to a baseline determined prior to administration of the patisiran pharmaceutical agent.

[0039] In some embodiments, the method results in a decrease in intraepidermal nerve fiber density in a skin biopsy compared to a baseline determined prior to administration of the patisiran pharmaceutical agent.

[0040] In some embodiments, the patient is administered the patisiran medication for at least 12 months, 18 months, 24 months, 30 months, or 36 months.

[0041] In some embodiments, the patient is in need of treatment for hereditary transthyretin-mediated amyloidosis with cardiomyopathy (hATTR amyloidosis), and the method results in improvement or stabilization of cardiac markers and / or echocardiographic parameters compared to a baseline determined prior to administration of the patisiran pharmaceutical agent.

[0042] In some embodiments, the cardiac marker is serum NT-proBNP concentration and the echocardiographic parameter is left ventricular (LV) strain or LV wall thickness.

[0043] In some embodiments, the method further comprises administering to the patient the following premedications: dexamethasone, oral paracetamol / acetaminophen, diphenhydramine, and ranitidine.

[0044] In some embodiments, the method further comprises administering to the patient a premedication: a. IV dexamethasone 10 mg, or equivalent, and b. Oral paracetamol / acetaminophen 500 mg, or equivalent, and c. IV histamine H1 receptor antagonists (H1 blockers): Diphenhydramine 50 mg, or other equivalent IV H1 blockers, or hydroxyzine 25 mg, or fexofenadine 30 or 60 mg PO, or cetirizine 10 mg PO, and d. IV histamine H2 receptor antagonists (H2 blockers): Ranitidine 50 mg or Famotidine 20 mg, or equivalent doses of other H2 blockers.

[0045] In some embodiments, the premedication is administered about one hour prior to each patisiran medication administration.

[0046] In some embodiments, the method further comprises administering to the patient an oral daily dose of the USDA Recommended Daily Allowance of Vitamin A.

[0047] In some embodiments, the method further comprises administering a tetramer stabilizing agent.

[0048] In some embodiments, the tetramer stabilizer is tafamidis or diflunisal.

[0049] In some embodiments, the patient is a. Are white; and / or b. resides in North America; and / or c. Are 65 years of age or older; and / or D. You are male, and / or e. Have stage I FAP, and / or f. Have stage II FAP, and / or g. Have a baseline mNIS+7 score between 8 and 165; and / or h. Have the Val30 Met TTR mutation, and / or i. Have one or more TTR mutations found in Table X; and / or j. Have echocardiographic evidence of cardiac amyloid involvement; and / or k. Previous history of long-term use of TTR tetramer stabilizers.

[0050] In some embodiments, the patient has a polyneuropathy and / or a cardiomyopathy.

[0051] In some embodiments, the patient does not have polyneuropathy and / or cardiomyopathy.

[0052] In some embodiments, the patient has a TTR-related disorder.

[0053] In some embodiments, the TTR-related disorder is selected from the group consisting of familial amyloid polyneuropathy (FAP), hereditary transthyretin-mediated amyloidosis (ATTR), syndromic polyneuropathy, familial amyloid cardiomyopathy (FAC), and leptomeningeal / CNS (central nervous system) amyloidosis.

[0054] In some embodiments, administration of the at least one agent is performed by the patient.

[0055] In some embodiments, the administration of the at least one agent is performed by a medical professional.

[0056] In some embodiments, administration is carried out over 80 minutes.

[0057] In some embodiments, the baseline is an average. [Brief description of the drawings]

[0058] [Figure 1] FIG. 1 is a graph showing the relationship between progression in ΔNIS or ΔmNIS+7 and TTR concentration.

[0059] [Diagram 2] FIG. 2 is a graph showing the relationship between progression in ΔNIS or ΔmNIS+7 and TTR concentration.

[0060] [Figure 3-1] Figure 3 shows the structural formulas of the sense and antisense strands of patisiran. Figure 3 discloses SEQ ID NOs: 1 and 2 in order of appearance. [Figure 3-2] Same as above.

[0061] [Figure 4] FIG. 4 is a graph showing improvement in neuropathy compared to baseline.

[0062] [Diagram 5] FIG. 5 shows the effect of patisiran on mNIS+7.

[0063] [Figure 6] Figure 6 shows the effect of patisiran on other secondary endpoints.

[0064] [Figure 7] FIG. 7 is a graph showing serum TTR concentrations in study participants.

[0065] [Figure 8] FIG. 8 shows the relationship between serum TTR reduction and mNIS+7 score at 18 months.

[0066] [Figure 9-1] FIG. 9 shows the shift in both PND scores and FAP status at 18 months. [Figure 9-2] Same as above.

[0067] [Figure 10] FIG. 10 is a graph showing the results of study participants in an 18-month double-blind study treated with patisiran for 12 months.

[0068] [Figure 11] FIG. 11 is a graph showing the outcomes of study participants over the 24 month period of the study.

[0069] [Figure 12A] 12A and 12B show graphs of change in pressure-volume loops (FIG. 12A) and isovolumic pressure-volume area (FIG. 12B) at 9 months (dashed lines) compared to baseline (solid lines) and stratified by treatment group. [Figure 12B] Same as above.

[0070] [Figure 13A] 13A and 13B show graphs of change in pressure-volume loops (FIG. 13A) and isovolumic pressure-volume area (FIG. 13B) at 18 months (dashed lines) compared to baseline (solid lines) and stratified by treatment group. [Figure 13B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0071] As described in more detail below, disclosed herein are methods of treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) (with or without polyneuropathy and / or cardiomyopathy) in a human patient in need thereof, the method comprising administering to the patient a patisiran pharmaceutical agent as described in Tables 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein patisiran is administered intravenously once every three weeks, and the method results in stabilization or improvement of FAP stage, PND score, modified Neuropathy Impairment Score (mNIS+7) or other neuropathy-related clinical endpoint, serum percent TTR concentration, cardiac markers and / or echocardiographic parameters. Also disclosed are methods for reducing or arresting an increase in the Neuropathy Impairment Score (NIS) or corrected NIS (mNIS+7) in a human subject in need thereof by administering an effective amount of a transthyretin (TTR) inhibitor composition, such that the effective amount reduces the concentration of TTR protein in serum by less than 50 μg / ml or by at least 80%.

[0072] In one embodiment, the TTR inhibitor composition is patisiran, e.g., the patisiran pharmaceutical agent, which is a TTR-specific small interfering ribonucleic acid (siRNA) formulated in a hepatotropic lipid nanoparticle (LNP) for intravenous (IV) administration.

[0073] TTR Inhibitory Compositions The methods described herein include administration of a TTR inhibitor composition. The TTR inhibitor composition can be any compound that reduces the concentration of TTR protein in the serum of a human subject. Examples include, but are not limited to, RNAi, such as siRNA. Examples of siRNA include siRNA that targets the TTR gene, such as patisillin (described in more detail below) and revusiran. Examples also include antisense RNA. Examples of antisense RNA that targets the TTR gene can be found in U.S. Patent No. 8,697,860.

[0074] The TTR inhibitor composition inhibits the expression of the TTR gene. As used herein, "transthyretin" ("TTR") refers to a gene in a cell. TTR is also known as ATTR, HsT2651, PALB, prealbumin, TBPA, and transthyretin (prealbumin, amyloidosis type I). The sequence of the human TTR mRNA transcript can be found in NM_000371. The sequence of the mouse TTR mRNA can be found in NM_013697.2, and the sequence of the rat TTR mRNA can be found in NM_012681.1.

[0075] The terms "silence," "inhibit expression of," "downregulate expression of," "suppress expression of," and the like, insofar as they refer to the TTR gene, refer herein to at least partial inhibition of expression of the TTR gene, as indicated by a reduction in the amount of mRNA in which the TTR gene is transcribed and which can be isolated from a first cell or population of cells that have been treated such that expression of the TTR gene is inhibited, compared to a second cell or population of cells that are substantially identical to the first cell or population of cells but have not been so treated (control cells). The degree of inhibition can be expressed by:

number

[0076] -

[0077] Alternatively, the degree of inhibition can be given in terms of the reduction of a parameter that is functionally linked to TTR gene expression, such as the amount of protein encoded by TTR gene secreted by cells, or the number of cells that show a certain phenotype, such as apoptosis.In principle, TTR gene silencing can be determined in any cell that expresses the target, either constitutively or by genome engineering, and by any suitable assay.However, if a reference is required to determine whether a given dsRNA inhibits the expression of TTR gene to some extent and therefore is encompassed by the present invention, the assay provided in the following examples shall serve as such a reference.

[0078] RNAi In some embodiments, the methods described herein use a TTR inhibitor composition that is an RNAi, e.g., an siRNA, e.g., a dsRNA, to inhibit expression of the TTR gene. In one embodiment, the siRNA is a dsRNA that targets the TTR gene. The dsRNA comprises an antisense strand having a complementary region that is complementary to at least a portion of the mRNA formed upon expression of the TTR gene, the complementary region being less than 30 nucleotides in length, and generally 19-24 nucleotides in length. The dsRNA of the present invention may further comprise one or more single-stranded nucleotide overhangs. TTR inhibitor siRNAs are described in International Patent Application No. PCT / US2009 / 061381 (WO2010 / 048228) and International Patent Application No. PCT / US2010 / 055311 (WO2011 / 056883), both of which are incorporated herein by reference in their entireties.

[0079] In one embodiment, the TTR inhibitory composition is patisiran, which is described in more detail below. In another embodiment, the TTR inhibitory composition is revusiran, a TTR-specific siRNA conjugated to a trivalent GalNAc carbohydrate cluster. A complete description of revusiran can be found in International Application No. PCT / US2012 / 065691 and US Patent Publication No. US20140315835, the contents of which are incorporated by reference in their entirety.

[0080] dsRNA comprises two RNA strands that are sufficiently complementary to hybridize and form a double-stranded structure. One strand of dsRNA (antisense strand) comprises a complementary region that is substantially complementary, and generally completely complementary, to the target sequence derived from the sequence of the mRNA formed during the expression of the TTR gene, and the other strand (sense strand) comprises a region that is complementary to the antisense strand, so that when combined under suitable conditions, the two strands hybridize and form a double-stranded structure. The term "antisense strand" refers to the strand of dsRNA that comprises a region that is substantially complementary to the target sequence. As used herein, the term "complementary region" refers to the region on the antisense strand that is substantially complementary to a sequence, e.g., a target sequence, as defined herein. When the complementary region is not completely complementary to the target sequence, mismatches are most tolerated in the terminal regions, and when present, they are generally in the terminal regions, e.g., within 6, 5, 4, 3, or 2 nucleotides of the 5'-end and / or 3'-end. The term "sense strand" as used herein refers to the strand of dsRNA that contains a region that is substantially complementary to a region of the antisense strand. Generally, the double-stranded structure is between 15-80, or between 15-60, or between 15-30, or between 25-30, or between 18-25, or between 19-24, or between 19-21, or 19, 20, or 21 base pairs in length. In one embodiment, the double strand is 19 base pairs in length. In another embodiment, the double strand is 21 base pairs in length.

[0081] Each strand of the dsRNA is generally between 15-80, or 15-60, or 15-30, or between 18-25, or 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In other embodiments, each strand is 25-30 nucleotides in length. Each strand of the duplex may be the same length or different lengths. When two different siRNAs are used in combination, the length of each strand of each siRNA may be the same or different.

[0082] The dsRNA may include one or more single-stranded overhangs of one or more nucleotides. In one embodiment, at least one end of the dsRNA has a single-stranded nucleotide overhang of 1-4, typically 1 or 2 nucleotides. In another embodiment, the antisense strand of the dsRNA has an overhang of 1-10 nucleotides at each 3'-end and 5'-end on the sense strand. In a further embodiment, the sense strand of the dsRNA has an overhang of 1-10 nucleotides at each 3'-end and 5'-end on the antisense strand.

[0083] As used herein, unless otherwise indicated, the term "complementary" when used to describe a first nucleotide sequence in the context of a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising a first nucleotide sequence to hybridize to form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising a second nucleotide sequence, as would be understood by one of skill in the art. Such conditions may be, for example, stringent conditions, which may include 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50°C or 70°C for 12-16 hours, followed by washing. Other conditions may be applied, such as physiologically relevant conditions that may be encountered in an organism. A person skilled in the art will be able to determine the most appropriate set of conditions for testing the complementarity of two sequences depending on the ultimate use of the hybridized nucleotides.

[0084] This includes base pairing of an oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of the first and second nucleotide sequences. Such sequences may be referred to herein as being "fully complementary" to each other. However, as used herein, when a first sequence is "substantially complementary" to a second sequence, the two sequences may be fully complementary or they may form one or more, but generally no more than four, three, or two mismatched base pairs upon hybridization while maintaining the ability to hybridize under conditions most relevant to their end use. However, when two oligonucleotides are designed to form one or more single-stranded overhangs upon hybridization, such overhangs shall not be considered as mismatches for purposes of determining complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, where the longer oligonucleotide comprises a 21 nucleotide sequence that is perfectly complementary to the shorter oligonucleotide, may still be referred to as "fully complementary" for purposes described herein.

[0085] "Complementary" sequences, as used herein, may also include or be formed entirely from non-Watson-Crick base pairs and / or base pairs formed from non-natural modified nucleotides, so long as they meet the above requirements regarding their ability to hybridize. Such non-Watson-Crick base pairs include, but are not limited to, G:U wobble or Hoogsteen type base pairs.

[0086] The terms "complementary," "fully complementary," and "substantially complementary" herein may be used in reference to base matching between the sense and antisense strands of a dsRNA, or between the antisense strand of a dsRNAi and a target sequence, as will be understood from the context of their use.

[0087] As used herein, a polynucleotide that is "substantially complementary to at least a portion of" a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of an mRNA of interest (e.g., an mRNA encoding TTR) that includes the 5'UTR or 3'UTR that is an open reading frame. For example, a polynucleotide is complementary to at least a portion of a TTR mRNA if the sequence is substantially complementary to an uninterrupted portion of an mRNA encoding TTR.

[0088] dsRNA can be synthesized by standard methods known in the art, for example, using an automated DNA synthesizer, such as those commercially available from Biosearch, Applied Biosystems, Inc., as discussed further below.

[0089] modified dsRNA In some embodiments, the dsRNA used in the methods described herein is chemically modified to enhance stability. The nucleic acids featured in the present invention can be synthesized or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry," Beaucage, SLet al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is incorporated herein by reference. Specific examples of dsRNA compounds useful in the present invention include dsRNAs that contain modified backbones or do not contain natural internucleoside linkages. As defined herein, dsRNAs with modified backbones include dsRNAs that retain a phosphorus atom in the backbone and dsRNAs that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referred to in the art, modified dsRNAs that do not have a phosphorus atom in the internucleoside backbone can also be considered to be oligonucleosides.

[0090] Modified dsRNA backbones include, for example, phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkyl phosphotriester, methyl and other alkyl phosphonates, including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates, including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thiono phosphoramidates, thiono alkyl phosphonates, thiono alkyl phosphotriesters, and boranophosphates with normal 3'-5' linkages, their 2'-5' linkages analogs, and those with reversed polarity, where adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.Also include various salts, mixed salts, and free acid forms.

[0091] Representative United States patents which teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808, 4,469,863, 4,476,301, 5,023,243, 5,177,195, 5,188,897, 5,264,423, 5,276,019, 5,278,302, 5,286,717, 5,321,131, 5,399,676, Nos. 5,405,939, 5,453,496, 5,455,233, 5,466,677, 5,476,925, 5,519,126, 5,536,821, 5,541,316, 5,550,111, 5,563,253, 5,571,799, 5,587,361, and 5,625,050, each of which is incorporated herein by reference.

[0092] Modified dsRNA backbones that do not contain phosphorus atoms in the backbone have backbones formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatom or heterocyclic internucleoside linkages, including those with morpholino linkages (formed in part from the sugar portion of the nucleoside), siloxane backbones, sulfide, sulfoxide and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl and thioformacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and N, O, S and CH 2 Others have mixed component parts.

[0093] Representative United States patents which teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent Nos. 5,034,506, 5,166,315, 5,185,444, 5,214,134, 5,216,141, 5,235,033, 5,64,562, 5,264,564, 5,405,938, 5,434,257, 5,466,677, and 5,470,967. Nos. 5,489,677, 5,541,307, 5,561,225, 5,596,086, 5,602,240, 5,608,046, 5,610,289, 5,618,704, 5,623,070, 5,663,312, 5,633,360, 5,677,437, and 5,677,439, each of which is incorporated herein by reference.

[0094] In other suitable dsRNA mimics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with appropriate nucleic acid target compounds. One such oligomeric compound, a dsRNA mimic that has been shown to have excellent hybridization properties, is called peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of dsRNA is replaced with an amide-containing backbone, particularly an aminoethylglycine backbone. The nucleobases are retained and are directly or indirectly linked to the aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082, 5,714,331, and 5,719,262, each of which is incorporated herein by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

[0095] Other embodiments of the invention include dsRNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, particularly those with the --CH2 --NH--CH 2 -, --CH 2 --N(CH 3 )--O--CH 2 --[(also known as the methylene(methylimino) or MMI backbone)], --CH 2 --O--N(CH 3 )--CH 2 --, --CH 2 --N(CH 3 )--N(CH 3 )--CH 2 -- and --N(CH 3 )--CH 2 --CH 2 --[The natural phosphodiester backbone is --O--P--O--CH 2 --], and the amide backbone of the above-referenced U.S. Patent No. 5,602,240. Also preferred are dsRNAs having morpholino backbone structures of the above-referenced U.S. Patent No. 5,034,506.

[0096] Modified dsRNAs may also contain one or more substituted sugar moieties. Preferred dsRNAs contain one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl are substituted or unsubstituted C 1 ~C 10 Alkyl or C 2 ~C 10 Alkenyl and alkynyl are preferred. Particularly preferred are O[(CH 2 ) n O] m CH 3 , O(CH 2 ) n OCH 3 , O(CH 2 ) n NH 2 , O(CH 2 ) n CH 3 , O(CH 2 ) n O.N.H. 2, and O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 where n and m are from 1 to about 10. Other preferred dsRNAs contain one of the following at the 2' position: 1 ~C 10 Lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , S.O. 2 CH 3 , O.N.O. 2 , NO 2 , N 3 , N.H. 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleaving groups, reporter groups, intercalators, groups for improving the pharmacokinetic properties of dsRNA, or groups for improving the pharmacodynamic properties of dsRNA, and other substituents with similar properties. Preferred modifications include 2'-methoxyethoxy (2'-O-CH 2 CH 2 OCH 3 , also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504), i.e., an alkoxy-alkoxy group. Further exemplary modifications include 2'-dimethylaminooxyethoxy, also known as 2'-DMAOE, i.e., O(CH 2 ) 2 ON(CH 3 ) 2 groups, and also described herein below in the Examples, 2'-dimethylaminoethoxyethoxy (known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O--CH 2 --O--CH2 --N(CH 2 ) 2 Examples include:

[0097] Other preferred modifications include 2'-methoxy (2'-OCH 3 ), 2'-aminopropoxy (2'-OCH 2 CH 2 CH 2 NH 2 ) and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the dsRNA, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNA and the 5' position of the 5' terminal nucleotide. DsRNAi can also have sugar mimetics, such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957, 5,118,800, 5,319,080, 5,359,044, 5,393,878, 5,446,137, 5,466,786, 5,514,785, 5,519,134, 5,567,811, 5,576, Nos. 427, 5,591,722, 5,597,909, 5,610,300, 5,627,053, 5,639,873, 5,646,265, 5,658,873, 5,670,633, and 5,700,920, some of which are commonly owned with the present application and each of which is incorporated herein by reference in its entirety.

[0098] dsRNA may also include modifications or substitutions of nucleobases (often simply referred to in the art as "bases"). As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine. , 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and adenine, 8-azaguanine and adenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, JL, ed. John Wiley & Sons, 1990, those disclosed in Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed in Sanghvi, Y S., Chapter 15, DsRNA Research and Applications, pages 289-302, Crooke, ST and Lebleu, B., Ed., CRC Press, 1993.Some of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the present invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitution has been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, YS, Crooke, ST and Lebleu, B., Eds., DsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp.276-278), and is an exemplary base substitution, even more specifically when combined with 2'-O-methoxyethyl sugar modification.

[0099] Representative United States patents which teach the preparation of some of the above-mentioned modified nucleobases as well as other modified nucleobases include, but are not limited to, the above-mentioned U.S. Patent No. 3,687,808, as well as U.S. Patent Nos. 4,845,205, 5,130,30, 5,134,066, 5,175,273, 5,367,066, 5,432,272, 5,457,187, 5,459,255, 5,4 Nos. 84,908, 5,502,177, 5,525,711, 5,552,540, 5,587,469, 5,594,121, 5,596,091, 5,614,617, and 5,681,941, each of which is incorporated herein by reference, as well as U.S. Pat. No. 5,750,692, which is also incorporated herein by reference.

[0100] Patisiran In one embodiment, the TTR inhibitor composition is patisiran. Patisiran is a small interfering ribonucleic acid (siRNA) specific for TTR that is formulated in liver-targeting lipid nanoparticles (LNPs) for intravenous (IV) administration (Akinc A, Zumbuehl A, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008; 26(5): 561-569). This TTR siRNA has a target region within the 3'UTR region of the TTR gene to ensure and confirm homology with WT TTR as well as all reported TTR mutations. After LNP-mediated delivery to the liver, patisiran targets TTR mRNA for degradation, resulting in a strong and sustained reduction of mutant and WT TTR protein via the RNAi mechanism.

[0101] TTR siRNA (also known as ALN-18328) consisted of sense and antisense strands with the following sequences, where lowercase letters indicate the 2'-O-methyl form of the nucleotides: Patisiran Drug Substance [Table 1]

[0102] Typically, the patisiran drug substance, i.e., the siRNA, is in the form of a pharma- ceutically acceptable salt. In some embodiments, the patisiran drug substance is patisiran sodium. The molecular formula of patisiran sodium is: 412 H 480 N 148 Na 40 O 290 P 40 and has a molecular weight of 14304 Da. The structural formulae of the sense and antisense strands are found in FIG.

[0103] The manufacturing process consists of synthesizing two single-stranded oligonucleotides of the duplex by conventional solid phase oligonucleotide synthesis. After purification, the two oligonucleotides are annealed to form a duplex.

[0104] The patisiran drug product is a sterile formulation of TTR siRNA ALN-18328 with lipid excipients (DLin-MC3-DMA, DSPC, cholesterol, and PEG2000-C-DMG) in isotonic phosphate-buffered saline solution.

[0105] Formulations of the patisiran drug product are shown below in Tables 1A, 1B, or 1C. In some embodiments, the concentration or amount of any one component is + / - 0.01, 0.05, 0.1, 0.5, 1.0, 5.0, or 10.0%, or the concentration or amount shown in the table. Table 1A: Composition of Patisiran Drug [Table 2] Table 1B: Composition of Patisiran Drug, per ml [Table 3] Table 1C: Composition of Patisiran Drug, per ml [Table 4]

[0106] In some embodiments, the patisiran pharmaceutical product is provided in a container, for example a glass vial, in the following amounts per vial: Table 2: Composition of Patisiran Drug, including per viral dose [Table 5]

[0107] The injectable patisiran solution contains 2 mg / mL of TTR siRNA drug substance. In some embodiments, the patisiran drug product is packaged in a 10 mL glass vial with a fill volume of 5.5 mL. In some embodiments, the patisiran drug product is packaged as a single-use vial at 10 mg in 5 ml.

[0108] In some embodiments, the container closure system consists of a United States Pharmacopoeia / European Pharmacopoeia (USP / EP) Type I borosilicate glass vial, a Teflon faced butyl rubber stopper, and an aluminum flip-off cap.

[0109] Tetramer stabilizers In some embodiments, the methods described herein comprise co-administration of a tetramer stabilizer and another TTR inhibition composition.

[0110] Tetramer stabilizers are compounds that bind to the TTR protein and act to stabilize the TTR tetramer. Mutations that destabilize the TTR tetramer result in mislocated and aggregated TTR.

[0111] Examples of tetramer stabilizers include tafamidis and diflunisal. Both tafamidis and diflunisal can slow the rate of disease progression (Berk et al., Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013,310:2658-2667; Coelho et al., 2012; Coelho et al., Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013,260:2802-2814; Lozeron et al., Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 2013,20:1539-1545).

[0112] Subjects and Diagnosis Disclosed herein is a method of treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof, the method comprising administering to the patient a patisiran pharmaceutical agent described in Table 1A, 1B, or 1C at a dose of 0.3 mg siRNA per kg body weight, wherein the patisiran is administered intravenously once every three weeks. In some embodiments, the method results in stabilization or improvement of cardiac function. In some embodiments, the method results in stabilization or improvement of FAP stage, PND score, modified Neuropathy Impairment Score (mNIS+7), or other neuropathy-related clinical endpoints, serum percent TTR concentration, cardiac markers, and / or echocardiographic parameters. In some embodiments, the patient has polyneuropathy and / or cardiomyopathy. In some embodiments, the patient does not have polyneuropathy and / or cardiomyopathy.

[0113] As used herein, the term "polyneuropathy" refers to a condition in which a person's peripheral nerves or nerves located outside the brain and spinal cord are damaged. Polyneuropathy often causes muscle weakness, paralysis, and pain, usually in the hands and feet. It can also affect other areas and bodily functions, including digestion, urination, and circulation. Polyneuropathy can result from traumatic injury, infection, metabolic problems, genetic causes, and exposure to toxins. There are two main categories of polyneuropathy: acute and chronic.

[0114] As used herein, the term "cardiomyopathy" refers to conditions that affect the heart muscle (myocardium). Cardiomyopathy can cause the heart to harden, enlarge, or thicken, leading to scar tissue. As a result, the heart cannot effectively pump blood to the rest of the body. Eventually, the heart weakens and cardiomyopathy can lead to heart failure. There may be no signs or symptoms in the early stages of cardiomyopathy. However, as the condition progresses, signs and symptoms usually appear, including shortness of breath during activity or at rest, swelling of the legs, ankles, and feet, abdominal distension due to fluid accumulation, coughing while lying down, difficulty sleeping lying down, fatigue, heartbeat that feels rapid, intense, or erratic, chest discomfort or pressure, dizziness, lightheadedness, and fainting. The most common types of cardiomyopathy are dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia (ARVD), restrictive cardiomyopathy, and transthyretin amyloid cardiomyopathy (ATTR-CM).

[0115] Also disclosed herein is a method for reducing or stopping the increase of the Neuropathy Impairment Score (NIS) or modified NIS (mNIS+7) in a human subject in need thereof. In some embodiments, the human subject has a TTR-related disorder. In some embodiments, the TTR-related disorder is one of the diseases caused by mutations in the transthyretin (TTR) gene. In one embodiment, the disease is TTR amyloidosis, which manifests in various forms such as familial amyloid polyneuropathy (FAP), transthyretin-mediated amyloidosis (ATTR), and symptomatic polyneuropathy. When the peripheral nervous system is more prominently affected, the disease is called FAP. When the heart is primarily involved but not the nervous system, the disease is called familial amyloid cardiomyopathy (FAC). The third major type of TTR amyloidosis is called leptomeningeal / CNS (central nervous system) amyloidosis. ATTR affects the autonomic nervous system.

[0116] In some embodiments, the human subject with TTR-related disorder has a mutant TTR gene. More than 100 reported TTR mutations show various disease symptoms. The most common mutations associated with FAP and ATTR-related cardiomyopathy are Val30Met and Val122Ile, respectively. TTR mutations cause protein misfolding, accelerate the process of TTR amyloid formation, and are the most important risk factor for the development of clinically significant TTR amyloidosis (also called ATTR (amyloidosis-transthyretin type)). More than 85 amyloidogenic TTR variants are known to cause systemic familial amyloidosis.

[0117] In some embodiments, a human subject is selected to receive treatment for any form of TTR amyloidosis if the human subject is an adult (>18 years of age) with biopsy-proven ATTR amyloidosis and mild to moderate neuropathy. In further embodiments, the human subject also has one or more of the following: Karnofsky Performance Status (KPS) >60%; Body Mass Index (BMI) 17-33 kg / m2 adequate hepatic and renal function (aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN), total bilirubin within normal range, albumin > 3 g / dL, and international normalized ratio (INR) ≤ 1.2; serum creatinine ≤ 1.5 ULN), and seronegativity for hepatitis B virus and hepatitis C virus.

[0118] In another embodiment, human subjects are excluded from treatment if they have had a liver transplant; have surgery planned during treatment; are HIV positive; have received an investigational drug other than tafamidis or diflunisal within 30 days; have a New York Heart Association heart failure classification of >2; are pregnant or breastfeeding; have known or suspected systemic bacterial, viral, parasitic, or fungal infection, unstable angina, uncontrolled clinically significant cardiac arrhythmias; or have previously had a severe reaction to a liposomal product or have known hypersensitivity to oligonucleotides.

[0119] Neuropathic Impairment Score (NIS) The method disclosed herein reduces or stops the increase of neuropathy impairment score (NIS) in a human subject in need thereof by administering a transthyretin (TTR) inhibitor composition. NIS refers to a scoring system that measures muscle weakness, sensation, and reflexes, especially in relation to peripheral neuropathy. NIS scores evaluate standard groups of muscle weakness (1 is 25% reduction, 2 is 50% reduction, 3 is 75% reduction, 3.25 is movement against gravity, 3.5 is movement with gravity removed, 3.75 is muscle contraction without movement, 4 is paralysis), muscle stretch reflex standard groups (0 is normal, 1 is reduced, 2 is absent), and touch, vibration, joint position and movement senses, and pain sense (all graded on index finger and big toe: 0 is normal, 1 is reduced, 2 is absent). Evaluation is corrected for age, sex, and physical strength.

[0120] In one embodiment, the method of reducing the NIS score results in a reduction in the NIS of at least 10%. In other embodiments, the method score results in a reduction in the NIS of at least 5, 10, 15, 20, 25, 30, 40, or at least 50%. In other embodiments, the method stops the increase in the NIS score, for example, results in a 0% increase in the NIS score.

[0121] Methods for determining NIS in a human subject are well known to those skilled in the art and can be found in:

[0122] Dyck, PJ et al., Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort, Neurology 1997.49(1):pgs.229-239).

[0123] Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetes. Muscle Nerve. 1988 Jan;11(1):21-32.

[0124] Modified Neuropathy Impairment Score (mNIS+7) In some embodiments, the methods disclosed herein reduce or stop the increase in modified neuropathy impairment score (mNIS+7) in a human subject in need thereof by administering a transthyretin (TTR) inhibitor composition. As known to those skilled in the art, mNIS+7 refers to a clinical trial-based assessment of neuropathy (NIS) combined with electrophysiological measures of small and large nerve fiber function (NCS and QST), and measurements of autonomic function (postural blood pressure).

[0125] The mNIS+7 score is a modification of the NIS+7 score (representing NIS+seven tests). The NIS+7 analyzes muscle weakness and muscle stretch reflexes. Five of the seven tests include attributes of nerve conduction. These characteristics are peroneal nerve compound muscle action potential amplitude, motor nerve conduction velocity and motor nerve distal latency (MNDL), tibial MNDL, and sural sensory nerve action potential amplitude. These values ​​are corrected for age, sex, height, and weight variables. The remaining two of the seven tests include vibration detection threshold and heart rate reduction with deep breathing.

[0126] The mNIS+7 score modifies the NIS+7 by taking into account the use of smart somatotopic quantitative sensory testing, a new autonomic assessment, and the compound muscle action potential amplitudes of the ulnar, peroneal, and tibial nerves, and the sensory nerve action potentials of the ulnar and peroneal nerves (Suanprasert, N. et al., Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials, J. Neurol. Sci., 2014. 344(1-2):pgs.121-128).

[0127] In one embodiment, the method of reducing the mNIS+7 score reduces mNIS+7 by at least 10%. In other embodiments, the method score results in at least a 5, 10, 15, 20, 25, 30, 40, or at least a 50% reduction in the mNIS+7 score. In other embodiments, the method stops the increase in mNIS+7, e.g., the method results in a 0% increase in mNIS+7.

[0128] Quality of life and neuropathy-related clinical outcomes In some embodiments, the methods disclosed herein stabilize or improve quality of life and / or neuropathy-related clinical endpoints. For example, the methods described herein can improve or stabilize quality of life, mobility, disability, walking speed, nutritional status, and / or autonomic symptoms in a human patient in need thereof, such as a human patient with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with or without polyneuropathy and / or cardiomyopathy, the method comprising administering to the patient a patisiran pharmaceutical agent described in Table 1A, 1B, or 1C at a dose of 0.3 mg siRNA per kg body weight, wherein patisiran is administered intravenously once every three weeks.

[0129] In some embodiments, the methods described herein can improve or stabilize at least one neuropathy-related clinical endpoint selected from the group consisting of Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN), NIS-W, Rasch-built Global Disability Score (R-ODS), 10-Meter Walk Test (10-MWT), modified Body Mass Index (mBMI), and COMPASS-31 score in a human patient in need thereof, such as a human patient having hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with or without polyneuropathy and / or cardiomyopathy, the methods comprising administering to the patient a patisiran pharmaceutical agent described in Table 1A, 1B, or 1C at a dose of 0.3 mg of siRNA per kg of body weight, wherein patisiran is administered intravenously once every three weeks.

[0130] FAP Stage and PND Score In some embodiments, the methods described herein stabilize or improve the polyneuropathy disorder (PND) score and familial amyloid polyneuropathy (FAP) stage described herein. The PND score is determined as follows: PND I: maintains walking, sensory impairment; PND II: walking impaired, but can walk without a cane or crutch; PND IIIA: walks with one cane or crutch; PND IIIB: walks with two canes or crutches; PND IV: wheelchair or bedbound. The FAP stages are as follows: FAP I: no walking impairment, FAP II: needs assistance walking, FAP III: wheelchair or bedbound.

[0131] Serum TTR protein concentration The method described herein includes administering to a human subject an effective amount of a transthyretin (TTR) inhibitor composition, e.g., patisiran, where the effective amount reduces the concentration of TTR protein in the serum of the human subject by less than 50 μg / ml or at least 80%. The serum TTR protein concentration can be determined directly using any method known to those skilled in the art, e.g., an antibody-based assay, e.g., an ELISA. Alternatively, the serum TTR protein concentration can be determined by measuring the amount of TTR mRNA. In a further embodiment, the serum TTR protein concentration is determined by measuring the concentration of a surrogate, e.g., vitamin A or retinol binding protein (RBP). In one embodiment, the serum TTR protein concentration is determined using an ELISA assay as described in the following examples.

[0132] In some embodiments, the serum TTR protein concentration is reduced to less than 50 μg / ml, or to less than 40 μg / ml, 25 μg / ml, or 10 μg / ml. In some embodiments, the serum TTR protein concentration is reduced by 80%, or by 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or 95%.

[0133] Cardiac markers and echocardiographic parameters In some embodiments, the methods described herein treat a patient in need of treatment for hereditary transthyretin-mediated amyloidosis with cardiomyopathy (hATTR amyloidosis), wherein the methods result in improvement or stabilization of cardiac markers and / or echocardiographic parameters compared to baseline.

[0134] An example of a cardiac marker is serum NT-proBNP concentration. An example of an echocardiographic parameter is left ventricular (LV) strain or LV wall thickness.

[0135] AUC AUC refers to the area under the curve of the concentration of a composition, such as TTR, in the plasma of the bloodstream over time after a dose of a drug, such as a TTR inhibitor composition, is administered to a patient.This is affected by the rate of absorption of the composition into the patient's plasma and the rate of removal from the patient's plasma.As those skilled in the art know, AUC can be determined by calculating the integral of the plasma composition concentration after the drug is administered.In another embodiment, AUC can be predicted using the following formula:

[0136] Prediction AUC = (D × F) / CL

[0137] where D is the dose concentration, F is a measure of bioavailability, and CL is the predicted clearance rate. Those skilled in the art will appreciate that the predicted AUC value has an error range of ±3-4 fold.

[0138] In some embodiments, the data for determining the AUC are obtained by taking blood samples from the patient at various time intervals following administration of the agent. In one aspect, the mean AUC in the patient's plasma following administration of the TTR inhibitor composition is in the range of about 9,000 to about 18,000.

[0139] It is understood that the plasma concentration of TTR may vary significantly between subjects due to variability in metabolism and / or possible interactions with other therapeutic agents. According to one aspect of the present invention, the plasma concentration of TTR may vary from subject to subject. Similarly, the maximum plasma concentration (C max) or the time to reach maximum plasma concentration (T max ), or the area under the curve from time zero to the time of the last measurable concentration (AUC last ), or total area under the plasma concentration time curve (AUC), may vary from subject to subject. Due to this variability, the amount necessary to constitute a "therapeutically effective amount" of a compound, such as a TTR inhibitor composition, may vary from subject to subject.

[0140] Pharmaceutical Compositions The methods described herein include administration of a TTR inhibitory composition, e.g., an siRNA that targets the TTR gene, e.g., patisiran. In some embodiments, the TTR inhibitory composition is a pharmaceutical composition.

[0141] As used herein, a "pharmaceutical composition" includes a TTR inhibitor composition and a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically does not include cell culture media. For orally administered agents, pharmaceutically acceptable carriers include, but are not limited to, pharmaceutically acceptable excipients such as inert diluents, disintegrants, binders, lubricants, sweeteners, flavoring agents, coloring agents, and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrants. Binders may include starch and gelatin, while lubricants, if present, are generally magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

[0142] The pharmaceutical composition of the present invention can be administered in several ways, depending on whether local or systemic treatment is desired and the area to be treated.Administration can be local, intrapulmonary, intratracheal, intranasal, epidermal and transdermal, oral or parenteral, for example by inhalation or insufflation of powder or aerosol by nebulizer, etc. Parenteral administration includes injection or infusion into intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular, or into brain, for example intraparenchymal, intrathecal or intraventricular administration.

[0143] The composition can be delivered in a manner that targets a specific tissue, such as the liver (e.g., the hepatocytes of the liver).The pharmaceutical composition can be delivered by direct injection into the brain.Injection can be by stereotactic injection into a specific region of the brain (e.g., the substantia nigra, cortex, hippocampus, striatum, or globus pallidus), or dsRNA can be delivered to multiple regions of the central nervous system (e.g., multiple regions of the brain, and / or into the spinal cord).dsRNA can also be delivered to diffuse regions of the brain (e.g., diffuse delivery to the brain cortex).

[0144] In one embodiment, the dsRNA targeting TTR can be delivered by a cannula or other delivery device with one end implanted in a tissue, for example, the brain, for example, the substantia nigra, cortex, hippocampus, striatum, corpus callosum or globus pallidus of the brain. The cannula can be connected to a reservoir of dsRNA composition. The flow or delivery can be mediated by a pump, for example, an osmotic pump or a minipump such as an Alzet pump (Durect, Cupertino, CA). In one embodiment, the pump and reservoir are implanted in an area remote from the tissue, for example, the abdomen, and delivery is by a conduit leading from the pump or reservoir to the release site. The infusion of the dsRNA composition into the brain can be for hours or days, for example, 1, 2, 3, 5, or 7 days or more. Devices for delivery to the brain are described, for example, in U.S. Patent Nos. 6,093,180 and 5,814,014.

[0145] Dosage and Timing Those skilled in the art will appreciate that certain factors, including but not limited to, the severity of the disease or disorder, previous treatments, the general health and / or age of the subject, and other diseases present, may affect the dosage and timing required to effectively treat a subject. Moreover, treatment of a subject with a composition in a therapeutically effective amount may include a single treatment or a series of treatments. Estimation of effective doses and in vivo half-lives of TTR inhibitor compositions encompassed by the present invention can be made using conventional methodologies or based on in vivo testing using appropriate animal models, as described elsewhere herein.

[0146] Generally, suitable dosages of the pharmaceutical composition of the TTR inhibitor composition will be in the range of 0.01 to 200.0 milligrams per kilogram of recipient body weight per day, generally in the range of 1 to 50 mg per kilogram of body weight per day.

[0147] For example, the TTR inhibitor composition may be an siRNA and may be administered at 0.01 mg / kg, 0.05 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.628 mg / kg, 2 mg / kg, 3 mg / kg, 5.0 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, 40 mg / kg, or 50 mg / kg per single dose. In another embodiment, the dosage is between 0.15 mg / kg and 0.3 mg / kg. For example, the TTR inhibitor composition can be administered at a dose of 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, or 0.3 mg / kg. In one embodiment, the TTR inhibitor composition is administered at a dose of 0.3 mg / kg.

[0148] The pharmaceutical composition (e.g., patisiran) may be administered once a day, or once or twice every 5, 10, 15, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days. The dosage unit may be formulated for delivery over several days, for example, using a conventional sustained release formulation that provides sustained release of the TTR inhibitor composition over several days. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at specific sites, such as those that may be used in conjunction with the agents of the present invention.

[0149] In one embodiment, the TTR inhibitor composition is patisiran, e.g., patisiran pharmaceutical, and the dose is 0.3 mg / kg, and the dose is administered once every 21 days or 3 weeks. In some embodiments, the dose, e.g., an effective amount, is administered about every 3 weeks or about every 21 days. In another embodiment, the effective amount is 0.3 mg / kg, and the effective amount is administered once every 21 days or 3 weeks via a 70 minute infusion at 1 mL / min for 15 minutes followed by 3 mL / min for 55 minutes. In another embodiment, the effective amount is 0.3 mg / kg, and the effective amount is administered twice every 21 to 28 days via a 60 minute infusion at 3.3 mL / min, or via a 70 minute infusion at 1.1 mL / min for 15 minutes followed by 3.3 mL / min for 55 minutes.

[0150] In some embodiments, the method includes administering patisiran, e.g., patisiran pharmaceutical product, at a dosage of 0.3 mg siRNA per kg body weight administered by intravenous infusion over about 80 minutes once every 3 weeks. In some embodiments, the method includes administering patisiran at a dosage of 0.3 mg siRNA per kg body weight administered by intravenous infusion at 3.3 mL / min over 60 minutes, or using a microdosing regimen (1.1 mL / min for 15 minutes, followed by 3.3 mL / min for the remaining dose) over 70 minutes.

[0151] The dosage of the TTR inhibitor composition can be adjusted to treat an increase in NIS or FAP by administering the TTR inhibitor composition and determining the level of TTR protein in the subject. If the level of TTR protein is greater than 50 μg / ml, then the amount of the TTR inhibitor composition administered to the subject is increased, and if the level of TTR protein is less than 50 μg / ml, then the amount of the TTR inhibitor composition administered to the subject is decreased.

[0152] The TTR inhibitor composition can be administered in combination with other known drugs that are effective in treating pathological processes mediated by target gene expression.In one embodiment, patisiran is administered together with a tetramer stabilizer, such as tafamidis or diflunisal.In any case, the administering physician can adjust the amount and timing of patisiran and / or tetramer stabilizer administration based on the results observed using standard measures of effectiveness known in the art or described herein. Working Example

[0153] The following are examples of specific embodiments for carrying out the present invention. The examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but, of course, some experimental error and deviation should be allowed for.

[0154] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology within the skill of the art. Such techniques are explained fully in the literature, see, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993); ALLehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods in Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3rd Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); rd Ed. (Plenum Press) Vols A and B (1992).

[0155] The terms "patisiran" and "patisiran drug product" are used interchangeably in the Examples and refer to siRNA formulated as described in Tables 1A, 1B, and 1C. EXAMPLES

[0156] Example 1. Safety and Efficacy of Patisiran for TTR Amyloidosis In a Phase I clinical trial, patisiran was found to reduce TTR levels in patients over a 28-day period. The results of this study were published in the New England Journal of Medicine (Coelho et al., N Engl J Med 2013;369:819-29.). The publication is incorporated by reference for all purposes. A summary of the study design and results is also presented as follows:

[0157] The study was multicenter, randomized, single-blind, placebo-controlled, and dose-ranging, and evaluated the safety and efficacy of a single dose of patisiran in patients with TTR amyloidosis or healthy adults. Men and women aged 18-45 years were eligible for the study if they were healthy (determined based on medical history, physical examination, and 12-lead electrocardiogram), had a BMI of 18.0-31.5, had adequate liver function and blood counts, and were not of childbearing potential.

[0158] Series of participants (four in each series) were randomly assigned to receive patisiran at doses of 0.01–0.5 mg / kg or placebo (normal saline) in a 3:1 ratio. Patisiran was administered intravenously over 15 and 60 minutes, respectively. In the trials, patients received similar premedications the night before and the day of infusion to reduce the risk of infusion-related reactions. These medications included dexamethasone, acetaminophen, diphenhydramine or cetirizine, and ranitidine.

[0159] Patisiran pharmacodynamic activity was measured using a validated enzyme-linked immunosorbent assay (ELISA) for total TTR, reflecting serum TTR levels (Charles River Laboratories, Wilmington MA). Baseline levels of TTR, retinol-binding protein, and vitamin A for each patient were defined as the mean of four measurements taken before administration of patisiran. Adverse events were monitored from the start of drug administration through day 28. Safety monitoring also included hematological evaluations, blood chemistry analyses, and thyroid function tests.

[0160] The plasma pharmacokinetics of TTR siRNA contained in patisiran was assessed by a validated ELISA-based hybridization assay. The ATTO-Probe-HPLC assay (lower limit of quantification, 1.0 ng / milliliter) (Tandem Laboratories, Salt Lake City UT) was used for detection and quantification of siRNA. Pharmacokinetic estimates were determined using WinNonlin (Pharsight, Princeton NJ).

[0161] Knockdown of TTR, vitamin A, and retinol binding protein was measured relative to baseline levels (data not shown).

[0162] result No significant changes in TTR levels were observed at the two lowest doses of patisiran (compared to placebo); however, substantial TTR knockdown was observed in all participants receiving doses between 0.15 and 0.5 mg / kg (data not shown). TTR knockdown was rapid, potent, and durable across all three dose levels, with highly significant changes compared to placebo through day 28 (P<0.001). Given the robust responses seen at 0.15 and 0.3 mg / kg, and the slow incremental improvement in response at 0.5 mg / kg, only one participant received the 0.5 mg / kg dose.

[0163] The kinetics of the response (data not shown) showed little variability between participants, particularly at doses of at least 0.3 mg / kg, with a >50% decline by day 3, nadir levels by approximately day 10, continued >50% suppression at day 28, and complete recovery by day 70. Maximum TTR knockdown for participants receiving 0.15 mg / kg, 0.3 mg / kg, and 0.5 mg / kg was 85.7%, 87.6%, and 93.8%, respectively. The mean nadirs at the 0.15 mg / kg and 0.3 mg / kg doses were 82.3% (95% confidence interval (CI), 67.7 to 90.3) and 86.8% (95% CI, 83.8 to 89.3), respectively, and these nadirs, when analyzed as either absolute TTR levels or percentage TTR knockdown, showed little variability between participants and were highly significant compared with placebo (P<0.001) (data not shown).

[0164] The degree of knockdown was such that it determined the duration of inhibition; in participants receiving 0.15 mg / kg and 0.3 mg / kg, the mean reduction at day 28 was 56.6% (95% CI, 11.6-78.7) and 67.1% (95% CI, 45.5-80.1), respectively, and in a single patient receiving 0.5 mg / kg, the reduction at day 28 was 76.8%. The TTR knockdown observed in humans at the 0.3 mg / kg dose was virtually identical to that observed in nonhuman primates at the same dose level (data not shown). These reductions in TTR by patisiran correlated with changes in levels of retinol-binding protein and vitamin A (data not shown).

[0165] The use of patisiran did not result in significant changes in hematological, liver, or renal measures, or in thyroid function, and there were no drug-related serious adverse events or discontinuations of study drug due to adverse events (data not shown).

[0166] The plasma pharmacokinetic profile of patisiran showed that peak plasma concentrations of TTR siRNA and area under the curve values ​​to the final day increased approximately dose-proportionally across the dose range tested (data not shown).

[0167] Specificity of Patisiran To further demonstrate the specificity of patisiran's effect, TTR was also measured in a group of healthy volunteers in a Phase 1 study of ALN-PCS containing siRNA targeting PCSK9 (a cholesterol-lowering target) formulated in the same type of lipid nanoparticles used in patisiran. A single dose of 0.4 mg / kg of ALN-PCS (so-called control siRNA) had no effect on TTR (data not shown), indicating that the effect of patisiran on TTR was due to specific targeting by siRNA, rather than a nonspecific effect of the lipid nanoparticle formulation.

[0168] Additional evidence supporting the specificity and mechanism of action of patisiran's pharmacodynamic effects was obtained using a 5'RACE (rapid amplification of complementary DNA ends) assay on blood samples obtained from participants receiving a dose of 0.3 mg / kg to detect predicted TTR mRNA cleavage products in circulating extracellular RNA. To collect blood samples, serum was obtained after centrifugation of clotted blood samples (pre-dose and 24 h post-dose from subjects) at 1200 × g for 20 min. Serum was centrifuged a second time at 1200 × g for 10 min to remove floating cellular material and then frozen. Thawed serum was mixed with lithium chloride (1 M final concentration) and incubated at 4 °C for 1 h. Samples were spun at 120,000 × g for 2 h at 4 °C to pellet the RNA, and total RNA was isolated from the pellet by Trizol extraction (Life Technologies, Grand Island, New York, USA) and isopropanol precipitation.

[0169] To detect TTR siRNA-mediated cleavage products, the isolated RNA was used for ligation-mediated RACE PCR using the GeneRacer kit (Life Technologies). The RNA was ligated to the GeneRacer adapter and reverse transcribed using a TTR-specific reverse primer (5'-aatcaagttaaagtggaatgaaaagtgcctttcacag-3') (SEQ ID NO: 3), followed by two rounds of PCR using the Gene Racer GR5' forward primer complementary to the adapter and a TTR-specific reverse primer (5'-gcctttcacaggaatgttttattgtctctg-3') (SEQ ID NO: 4). Nested PCR was performed using the GR5' nested primer and a TTR-specific reverse nested primer (5'-ctctgcctggacttctaacatagcatatgaggtg-3') (SEQ ID NO: 5). The PCR products were cloned using the TOPO-Blunt vector (Life Technologies). The cloned inserts were amplified by colony PCR using M13 forward and reverse primers. The amplicons were sequenced with T7 promoter primers at the Macrogen sequencing facility. Sequences from 96 clones were aligned to human TTR using CLC WorkBench.

[0170] TTR mRNA was detected in both pre-dose samples and in samples obtained 24 h after drug administration. Consistent with an RNAi mechanism, the predicted mRNA cleavage products were absent in pre-dose samples but present in post-dose samples from all three participants (data not shown).

[0171] The LC / MS / MS assay for quantification of wild-type and mutant TTR in human serum was certified and performed by Tandem Lab. Serum samples were digested using chymotrypsin and then processed by protein precipitation extraction before analysis by LC / MS / MS. Chymotryptic peptides TTRW-1, representing wild-type TTR, and V30M-1, representing mutant V30M, were monitored according to their unique mass-to-charge ratio transitions. Standard calibration curve data obtained with stable isotope-labeled peptides (TTRW-1-D8 and V30M-1-D8) were used to calculate the endogenous peptide fragments (TTRW-1 and V30M-1) in human serum samples. Peak area ratios relative to standards (i.e., TTRW-1-D8 relative to internal standards TTRW-L1-D16 and V30M-1-D8 relative to V30M-L1-D16) were used to generate linear calibration curves using 1 / x2 weighted least squares regression analysis. The qualified LC / MS / MS method achieved a lower limit of quantification (LLOQ) of 5 ng / ml with a standard curve ranging from 5 to 2500 ng / ml.

[0172] Example 2. Multiple-dose study of the safety and efficacy of patisiran therapy for familial amyloidotic polyneuropathy This Phase II clinical trial administered multiple doses of patisiran to patients with TTR-mediated FAP and evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending intravenous doses of patisiran in these patients. The data were presented at the International Symposium on Familial Amyloidotic Polyneuropathy (ISFAP) in November 2013.

[0173] Eligible patients had biopsy-proven ATTR amyloidosis and mild-moderate neuropathy; Karnofsky performance status (KPS) ≥ 60%; and body mass index (BMI) 17-33 kg / m 2Patients were excluded from treatment if they had a liver transplant; surgery was planned during the study; they were HIV positive; they had received an investigational drug other than tafamidis or diflunisal within 30 days; their New York Heart Association heart failure classification was >2; they were pregnant or breastfeeding; they had known or suspected systemic bacterial, viral, parasitic, or fungal infection, unstable angina, or uncontrolled clinically significant cardiac arrhythmias; or they had a previous severe reaction to a liposomal product or known hypersensitivity to oligonucleotides.

[0174] This was a multicenter, international, open-label, multiple-ascending dose Phase II study of patisiran in patients with FAP. Three patient cohorts received two doses of patisiran, each administered as an intravenous (IV) infusion. Cohorts 1-3 received two doses of patisiran 0.01, 0.05, and 0.15 mg / kg, respectively, every four weeks (Q4W), and cohorts 4 and 5 both received two doses of patisiran 0.3 mg / kg Q4W. All patients in cohorts 6-9 received two doses of patisiran 0.3 mg / kg every three weeks (Q3W). All patients received premedication prior to each patisiran infusion consisting of dexamethasone, paracetamol (acetaminophen), an H2 blocker (e.g., ranitidine or famotidine), and an H1 blocker (e.g., cetirizine, hydroxyzine, or fexofenadine) to reduce the risk of infusion-related reactions.Patisiran was administered IV over 60 minutes at 3.3 mL / min or over 70 minutes using a microdosing regimen (1.1 mL / min for 15 minutes, followed by the remainder of the dose at 3.3 mL / min).

[0175] Serum levels of total TTR protein were assessed for all patients using enzyme-linked immunosorbent assay (ELISA). In addition, wild-type and mutant TTR proteins were measured separately and specifically in serum for patients with the Val30Met mutation using a proprietary mass spectrometry method (Charles River Laboratories, Quebec, Canada). Serum samples were collected at screening and on the following days: 0, 1, 2, 7, 10, 14, 21, 22, 23 (Q3W only), 28, 29 (Q4W only), 30 (Q4W only), 31 (Q3W only), 35, 38 (Q4W only), and 42, 49, 56, 112, and 208 of follow-up.

[0176] Plasma concentration-time profiles of TTR siRNA were generated based on blood samples taken on day 0 and at the following time points: pre-dose (within 1 hour of scheduled dose start), end of infusion (EOI), 5 min, 10 min, and 30 min, and 1, 2, 4, 6, 24, 48, 168, 336, 504 (day 21, Q3W regimen only), and 672 h (day 28, Q4W regimen only) post-infusion. Additional samples were taken on days 84 and 180 for the Q4W regimen, and on days 35, 91, and 187 for the Q3W regimen. For cohorts 3–9, blood samples on day 0 EOI and 2 h post-infusion were also analyzed for both free and encapsulated TTR siRNA. Serum TTR siRNA was analyzed using a validated ATTO-Probe high-performance liquid chromatography (HPLC) assay (Tandem Laboratories, Salt Lake City, Utah, USA). PK analyses were performed using noncompartmental and / or compartmental evaluation of TTR siRNA plasma concentration-time data, and PK parameter estimates were determined using the validated software program WinNonlin®. Urine samples were analyzed for levels of excreted TTR siRNA and renal clearance (CL) was determined following dosing. R ) was measured.

[0177] Serum levels of vitamin A and retinol-binding protein (RBP) were measured at the same time points as specified for total TTR by HPLC and nephelometry, respectively (Biomins Specialized Medical Pathology, Lyon, France).

[0178] The mean and variance of TTR knockdown from baseline were calculated for the PP population, with baseline defined as the mean of all pre-dose values. PD data (natural log-transformed TTR vs. baseline) were analyzed using analysis of variance (ANOVA) and analysis of covariance (ANCOVA) with Tukey's post-hoc tests of individual pairwise comparisons (between dose levels). The lowest TTR level was defined as the lowest level per patient during the 28 days (21 days for the Q3W group) following each dose administration (first dose, second dose period: 1-28 days, 29-56 days and 1-21 days, 22-42 days for the Q4W and Q3W groups, respectively). The relationship of TTR vs. baseline to RBP or vitamin A, and to wild-type and V30M TTR levels, was investigated via linear regression. Dose proportionality of the patisiran components in PK parameters was assessed using power model analysis. AEs were coded using the Medical Dictionary for Clinical Trials and Association (MedDRA) coding system, version 15.0, and descriptive statistics provided for AEs, laboratory data, vital sign data, and ECG interval data. All statistical analyses were performed using SAS software, version 9.3 or higher. Efficacy and Pharmacodynamics: Mean (SD) baseline serum TTR protein levels were similar across dose cohorts: 272.9 (98.86), 226.5 (12.67), 276.1 (7.65), 242.6 (38.30), and 235.5 (44.45) μg / mL for the 0.01, 0.05, 0.15, 0.3 Q4W, and 0.3 mg / kg Q3W dose groups, respectively.

[0179] A significant reduction in TTR (p<0.001 by post hoc test following ANCOVA) was observed after the first and second doses of patisiran in the 0.3 mg / kg Q4W and Q3W cohorts compared to the 0.01 mg / kg dose cohort (data not shown). In patients with the Val30Met mutation, a very similar degree of knockdown was observed for wild-type and mutant TTR (data not shown). The level of serum TTR knockdown was correlated with RBP (r 2 =0.89, p<10 -15 ) and Vitamin A (r 2 =0.90, p<10 -15 ) was highly correlated with decreased circulating levels (data not shown).

[0180] Although patients receiving tafamidis or diflunisal had significantly increased baseline levels of serum TTR compared with patients not receiving stabilizer therapy (p<0.001 by ANOVA) (data not shown), patisiran treatment resulted in a similar degree of TTR knockdown in these two patient groups (data not shown).

[0181] Pharmacokinetics: Mean concentrations of patisiran TTR siRNA component decreased after EOI (data not shown) and there was no accumulation of siRNA after the second dose on days 21 / 28. Measurement of encapsulated and unencapsulated concentrations of TTR siRNA after each dose demonstrated the stability of the circulating LNP formulation. For both the first and second doses, the mean values ​​of maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-last) increased in a dose-proportional manner across the dose range tested. Cmax and AUC0-last after dose 1 and dose 2 were similar and there was no accumulation. Median terminal half-life of patisiran on days 0 and 21 / 28 was 39-59 hours for doses >0.01 mg / kg and was relatively unchanged when comparing doses 1 and 2 of each dose cohort.

[0182] These phase II data demonstrate that treatment of FAP patients with patisiran resulted in robust, dose-dependent, and statistically significant knockdown of serum TTR protein levels. A mean sustained reduction of TTR of >80% was achieved with two consecutive doses of patisiran 0.3 mg / kg administered every 3–4 weeks, with a maximum knockdown of 96% achieved in the Q3W group. These knockdown rates are consistent with those observed in a single ascending-dose, placebo-controlled phase I study of patisiran (Coelho et al. 2013a). Evidence in other systemic amyloidoses indicates that as little as a 50% reduction in disease-causing protein can result in clinical disease improvement or stabilization (Lachmann et al. 2003; Lachmann et al. 2007). The degree of TTR knockdown by patisiran was not affected by patients taking tafamidis or diflunisal, suggesting that these TTR stabilizer drugs do not interfere with the pharmacological activity of patisiran. In patients with the Val30Met mutation, patisiran suppresses the production of both mutant and wild-type TTR, the latter of which remains amyloidogenic in patients with late-onset FAP after liver transplantation (Yazaki et al., 2003; Liepnieks et al., 2010).

[0183] Example 3. Administration of patisiran reduces neurological impairment as measured by NIS and mNIS+7 An open-label extension (OLE) study was conducted in FAP patients using the protocol described in Example 2. Administration of patisiran resulted in a reduction in both NIS and mNIS+7.

[0184] Patients with FAP previously treated in a phase 2 study were eligible to proceed to the phase 2 OLE study. Patients were administered 0.30 mg / kg every 3 weeks for up to 2 years, with clinical endpoints assessed every 6 months. Study objectives included effects on neuropathy (mNIS+7 and NIS), quality of life, mBMI, disability, mobility, grip strength, autonomic symptoms, nerve fiber density in skin biopsies, cardiac-related disability (in the cardiac-related subgroup), and serum TTR levels.

[0185] Patient demographics are shown below. [Table 6]

[0186] Baseline characteristics included: [Table 7]

[0187] Administration of patisiran resulted in a reduction in serum TTR levels, as shown in the table below. Patisiran achieved a sustained serum TTR reduction of approximately 80%, with a further nadir of up to 88% between doses. [Table 8]

[0188] As shown in the table below, administration of patisiran resulted in a change in mNIS+7, as measured at 6 and 12 months. [Table 9]

[0189] Treatment with patisiran resulted in changes in NIS at 6 and 12 months, as shown in the table below. [Table 10]

[0190] The relationship between progression in ΔNIS or ΔmNIS+7 and TTR concentrations was investigated using linear regression as shown in Figures 1 and 2. TTR and mean pre-treatment trough [TTR] correlated with the change in mNIS+7 at 6 months.

[0191] NIS and mNIS+7 were measured at 0, 6, and 12 months. ΔNIS or ΔmNIS+7 from 0-6 months and 0-12 months were used as response variables. Predictor variables included two different measures of TTR concentration: area under the curve ("AUC") of TTR protein concentration, and mean percent knockdown relative to baseline at days 84 and 168 (for comparisons of 0-6 months) and days 84, 168, 273, and 357 (for comparisons of 0-12 months).

[0192] For both TTR measurements, "baseline" was defined as the mean of all pre-dose values. TTR AUC was calculated using raw TTR concentrations (μg / mL) and the trapezoidal method, starting from baseline values ​​(inserted at day 0) and extending to day 182 (for comparisons of 0 to 6 months) or day 357 (for comparisons of 0 to 12 months). Percentage knockdown relative to baseline was calculated at each scheduled time point. Linear regression was performed and P values ​​associated with testing the null hypothesis of no association between predictor and response variables were reported.

[0193] At 12 months, there was a mean change in mNIS+7 and NIS of -2.5 and 0.4 points, respectively, which compares favorably with the more rapid increases in mNIS+7 and NIS (e.g., increases of 10 to 18 points) estimated at 12 months from previous FAP studies in patient populations with similar baseline NIS. The favorable effect of patisiran on progression of neuropathy impairment scores correlated with the degree of TTR reduction. This indicates that reduction of serum TTR burden with patisiran translates into clinical benefit in FAP patients.

[0194] Example 4. A single randomized, double-blind, placebo-controlled Phase 3 study of patisiran in patients with hATTR amyloidosis with polyneuropathy. Study design The efficacy and safety of patisiran were evaluated in patients with hATTR amyloidosis with polyneuropathy in a single randomized, double-blind, placebo-controlled phase 3 study (APOLLO). The primary efficacy outcome measure was the change from baseline in the mNIS+7 composite neuropathy score at 18 months. Secondary outcomes included Norfolk QOL-DN quality of life scores, as well as measures of mobility (NIS-W), disability (R-ODS), gait speed (10-meter walk test), nutritional status (mBMI), and autonomic symptoms (COMPASS-31). Exploratory outcomes included cardiac measurements in patients with evidence of cardiac-related impairment at baseline, as well as measurements of dermal amyloid burden and nerve fiber density in skin biopsies.

[0195] overview: APOLLO met its primary endpoint (mNIS+7) and also showed highly statistically significant effects on Norfolk QOL-DN and all other secondary endpoints, demonstrating clinical benefit of patisiran in hATTR amyloidosis with polyneuropathy. More than 50% of patients treated with patisiran had improvement in neuropathy at 18 months compared to baseline.

[0196] Summary of the Clinical Trial Protocol: Patients were treated with patisiran as described above. Briefly, patients received patisiran (see Table 1) at a dose of 0.3 mg siRNA per kg body weight, administered intravenously every three weeks (Q3W). Patisiran was administered intravenously, for example, at 3.3 mL / min over 60 minutes, or over 70 minutes using a microdosing regimen (1.1 mL / min for 15 minutes, followed by the remaining dose at 3.3 mL / min).

[0197] In some embodiments, patients were premedicated, for example, the night before and / or the day of administration of patisiran infusion, for example, one hour before administration of patisiran infusion, to reduce the risk of infusion-related reactions. These drugs included dexamethasone, acetaminophen, diphenhydramine or cetirizine, and ranitidine. In some embodiments, the following premedication regimen can be used: IV dexamethasone 10mg, or equivalent; and oral paracetamol / acetaminophen 500mg, or equivalent; and IV histamine H1 receptor antagonist (H1 blocker): diphenhydramine 50mg, or equivalent other IV H1 blocker or hydroxyzine 25mg, or fexofenadine 30 or 60mg PO, or cetirizine 10mg PO; and IV histamine H2 receptor antagonist (H2 blocker): ranitidine 50mg, or famotidine 20mg, or equivalent other H2 blocker dose.

[0198] Baseline characteristics: APOLLO enrolled 225 patients (148 in patisiran and 77 in placebo). Patients were enrolled between December 2013 and January 2016 at 44 sites in 19 countries across North America, Europe, Asia-Pacific, and Central / South America. The majority of patients were white (72.4%), 74.2% were male, and most were older adults with a median age of 62 years (range 24-83 years). There was a similar proportion of patients with FAP stage I and FAP stage II, with mean mNIS+7 scores of 80.9 (range 8-165) and 74.6 (range 11-153.5) in the patisiran and placebo groups, respectively. Val30Met mutations were present in 42.7% of patients compared with 57.3% of non-Val30Met mutations. Echocardiographic evidence of cardiac amyloid involvement was present in 56%, and 52.9% of all patients had a history of TTR tetramer stabilizer use. Treatment groups were well balanced for age, sex, disease stage, baseline mNIS+7, and previous TTR tetramer stabilizer use. The patisiran group had more whites (76.4% vs. 64.9%), a higher proportion of patients with non-Val30Met mutations (62.2% vs. 48.1%), echocardiographic evidence of cardiac-related disorders at baseline (cardiac subpopulation, 60.8% vs. 46.8%), as well as more patients enrolled in North America (25% vs. 13%).

[0199] TTR genotype As mentioned previously, Val30Met mutations were present in 42.7% of patients compared with 57.3% of non-Val30Met mutations. The non-Val30Met mutations found in patients are listed below. [Table 11]

[0200] Disease Stage The stages of FAP are shown in the table below.

[0201] [Table 12]

[0202] Disposition: A total of 185 patients completed study treatment, with a higher rate of completers for patisiran (92.6% vs. 62.3% for patisiran and placebo, respectively).A total of 193 patients completed the study, with a higher rate of completers for patisiran (93.2% vs. 71.4% for patisiran and placebo, respectively).

[0203] Six (7.8%) placebo patients showed rapid disease progression (mNIS+7 increase of ≥ 24 points in line with FAP stage progression as determined by a clinical adjudication committee) at 9 months compared with one (0.7%) in the patisiran group.

[0204] In the placebo group, the main reasons for discontinuation of study treatment were subject withdrawal of consent (15.6%), as well as adverse events (9.1%), progressive disease (5.2%), and death (5.2%), and the main reasons for discontinuation of study participation were subject withdrawal of consent (14.3%), as well as adverse events (7.8%) and death (5.2%).

[0205] In the patisiran group, the main reasons for discontinuation of study treatment were death (3.4%) and adverse events (2%), and the main reasons for discontinuation of study participation were death (4.1%) and adverse events (1.4%).

[0206] Of 189 patients who completed APOLLO and were potentially eligible to enroll in the global open-label extension study, 186 (98.4%) were enrolled in the ongoing global open-label extension study.

[0207] Summary of Efficacy A summary of the results of both mNIS+7 and secondary endpoints is presented in the table below. [Table 13] [Table 14] [Table 15]

[0208] mNIS+7 The study met its primary efficacy endpoint. In the mITT (modified intention to treat) population, the patisiran group showed improvement in neuropathy at 18 months compared to baseline (mNIS+7 LS mean (SEM) change of -6.0 (1.7) points), whereas the placebo group showed worsening of neuropathy (mNIS+7 LS mean (SEM) change of +28.0 (2.6) points), indicating a highly significant reduction in neuropathy progression with patisiran compared to placebo (LS mean difference of -34.0 points, 95% CI: -39.9, -28.1, p=9.26E-24). Similar results were observed in the PP population. The effect of patisiran was observed as early as 9 months (LS mean difference of -16.0 points, 95% CI: -20.7, -11.3), and a consistent effect in favour of patisiran was seen across all components of the mNIS+7.

[0209] As shown in Figure 4, improvement in neuropathy compared to baseline (change in mNIS+7 of <0 points) at 18 months was seen in 56.1% of patients (95% CI: 48.1%, 64.1%) on patisiran compared to only 3.9% (95% CI: 0.0%, 8.2%) on placebo (odds ratio of 40.0, p=1.82E-15).

[0210] As shown in Figure 5, the effect of patisiran on mNIS+7 was observed across all patient subgroups defined by age, sex, ethnicity, geographic region, TTR genotype, neuropathy severity, disease stage, and prior use of TTR tetramer stabilizers.

[0211] Maintenance of efficacy of patisiran, as measured by mNIS+7 score, was observed in patients over 30 and 36 months of treatment regimens.

[0212] Secondary endpoints: The six secondary endpoints also met statistical significance per hierarchical testing.

[0213] As shown in Figure 6, in the mITT population, the LS mean (SEM) change from baseline at 18 months on the Norfolk QOL-DN was -6.7 (1.8) points for patisiran, representing an improvement in quality of life, compared to +14.4 (2.7) points for placebo, indicating a worsening of quality of life. The LS mean difference between the treatment groups was -21.1 points (95% CI: -27.2, -15.0, p=1.10E-10), indicating a significant improvement in quality of life with patisiran compared to placebo. Similar results were observed in the PP population.

[0214] Similar to mNIS+7, the effect of patisiran on Norfolk QOL-DN was seen as early as 9 months (LS mean difference of -15.0 points, 95% CI: -19.8, -10.2). The effect of patisiran on Norfolk QOL-DN was observed across all patient subgroups defined by age, sex, ethnicity, geographic region, TTR genotype, neuropathy severity, disease stage, and previous use of TTR tetramer stabilizers.

[0215] Patisiran treatment also led to significant improvements from baseline compared to placebo at 18 months in several additional secondary endpoints, including: NIS-W (LS mean difference of -17.9 points, 95% CI: -22.3, -13.4, p=1.40E-13), R-ODS (LS mean difference of +9.0 points, 95% CI: 7.0, 10.9, p=4.07E-16), Improvements were observed across all patient subgroups defined by age, sex, ethnicity, geographic region, TTR genotype, neuropathy severity, disease stage, and previous use of TTR tetramer stabilizers.

[0216] As shown in the table below, all secondary endpoints achieved statistical significance at 18 months. Separation was seen at 9 months for all secondary endpoints except COMPASS-31. Reference ranges were as follows: NIS-W: 0 (better) to 192 (worse), R-ODS: 0 (worse) to 48 (better), COMPASS 31: 0 (better) to 100 (worse). [Table 16]

[0217] Serum TTR reduction rate Serum TTR concentrations were measured in study participants. The mean percent reduction in serum TTR was 77.7% (min -38%, max 95%) in patients receiving patisiran compared with a reduction of only 5.8% (min -57%, max 43) with placebo. The effect of patisiran on serum TTR was observed across patient subgroups defined by age, sex, genotype, and previous use of TTR tetramer stabilizers. Greater TTR reduction also correlated with improved changes in both mNIS+7 scores with an R value of 0.52 (95% CI: -0.62, -0.41) and Norfolk QoL-DN scores with an R value of -0.40 (95% CI: -0.51, -0.27). Data are presented in Figure 7.

[0218] Greater TTR reduction correlated with improved change in mNIS+7 (R value 0.52 [95% CI: -0.62, -0.41]). Greater TTR reduction correlated with improved change in Norfolk QoL-DN (R value -0.40 [95% CI: -0.51, -0.27]). The graph in Figure 8 shows the relationship between serum TTR reduction and mNIS+7 score at 18 months.

[0219] PND score and FAP stage Patients were assessed for polyneuropathy disorder (PND) score and familial amyloid polyneuropathy (FAP) stage as described herein. PND score is determined as follows: PND I: walking maintained, sensory impairment; PND II: walking impaired but able to walk without cane or crutches; PND IIIA: walking with one cane or crutch; PND IIIB: walking with two canes or crutches; PND IV: wheelchair or bedbound. FAP stage is as follows: FAP I: no walking impairment, FAP II: needing assistance walking, FAP III: wheelchair or bedbound.

[0220] At 18 months, there was a shift in both PND scores and FAP status, as shown in Figure 9. Treatment with patisiran resulted in either stabilized or improved PND scores and FAP stage.

[0221] Skin biopsy: Nerve fiber density and cutaneous amyloid content Spontaneous skin biopsies were performed on study participants. Nerve fiber density and skin amyloid content were determined. Approximately 50% of placebo patients who underwent baseline skin biopsies did not have an 18-month follow-up sample due to dropout. This also added significant variability, limiting interpretation of the results. However, results showed an attenuated decrease in intraepidermal nerve fiber density (IENFD) with patisiran treatment compared to placebo (nominal p-value significant), and no significant change in sweat gland nerve fiber density (SGNFD) or skin amyloid content with patisiran treatment compared to placebo. (Data not shown).

[0222] Maintenance of Patisiran Efficacy Participants in the 18-month double-blind study were treated with patisiran for 12 months. The results are plotted in Figure 10 and show maintenance of patisiran effect on mNIS+7 over 30 months, as well as evidence of efficacy in patients who had previously received placebo.

[0223] Study participants in the 24-month study were treated with patisiran for 12 months. The results are shown in the graph in Figure 11, which shows the maintenance of patisiran effect on mNIS+7 over 36 months.

[0224] Cardiac subgroup analysis Cardiac subpopulations, e.g., patients with cardiomyopathy, have been described above. Generally, these were patients with a total heart thickness of 13 mm or greater and no evidence of hypertension or valvular heart disease. The cardiac subpopulation consisted of 36 (46.8%) patients in the placebo subpopulation and 90 (60.8%) patients in the patisiran group. The total number of patients in the cardiac subpopulation was 126, or 56% of the patients in the study.

[0225] Exploratory cardiac-related endpoints, such as cardiac markers and / or echocardiographic parameters, were assessed across the population. The results are shown in the table below. Exploratory Cardiac Endpoints [Table 17]

[0226] Patients receiving patisiran showed stabilization of NT-proBNP compared to placebo patients (patisiran: increase of 12.5 pmol / L; placebo: increase of 227.2 pmol / L). The difference in NT-proBNP between patisiran-treated and placebo patients was -214.6 pmol / L (p=0.0024). NT-proBNP markers in cardiac subgroups [Table 18] * Only patients with non-missing NT-proBNP at 18 months were included ‡ Only patients with baseline NT-proBNP ≥ 650ng / L and non-missing NT-proBNP at 18 months were included

[0227] Improvements were also seen in LV wall thickness and longitudinal strain in patients receiving patisiran. LV wall thickness decreased 0.1 cm compared to baseline in patisiran-treated patients compared to only 0.007 cm in placebo patients (p=0.0173). LV longitudinal strain also stabilized in patisiran patients and increased by only 0.08% compared to 1.46% in placebo patients (p=0.0154).

[0228] Example 5. Overview In some embodiments, the methods described herein are used to treat Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy and Polyneuropathy (hATTR) in a human patient in need thereof by administering patisiran of the composition set forth in Table 1 to the patient at a dose of 0.3 mg siRNA per kg body weight, wherein patisiran is administered intravenously once every 21 days or 3 weeks. The methods result in a reduction in the modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score from the subject's baseline score prior to administration of patisiran.

[0229] In some embodiments, the methods described herein are used to treat hereditary transthyretin-mediated amyloidosis with cardiomyopathy (hATTR) in a human patient in need thereof, the methods comprising administering patisiran of a composition as set forth in Table 1 to the patient at a dose of 0.3 mg of siRNA per kg of body weight, wherein patisiran is administered intravenously once every 21 days or three weeks.

[0230] In some embodiments, the methods described herein are used to reduce the modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score in a human patient having and treating Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy and Polyneuropathy (hATTR), the method comprising administering to the patient patisiran of a composition as set forth in Table 1 at a dose of 0.3 mg of siRNA per kg of body weight, wherein the patisiran is administered intravenously once every 21 days or 3 weeks, the method results in a reduction in the modified Neuropathy Impairment Score (mNIS+7) composite neuropathy score from baseline determined at 18 months, the baseline being the patient's mNIS+7 score prior to administration of patisiran.

[0231] In some embodiments, the method results in an improvement from baseline in one or more endpoints selected from the group consisting of Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN), NIS-W, Rasch-built Global Disability Score (R-ODS), 10-meter walk test, modified body mass index (mBMI), and COMPASS-31 score. In some embodiments, the method results in an improvement in all endpoints. In some embodiments, the method results in an improvement in Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN) and COMPASS-31 score and 10-meter walk test.

[0232] In some embodiments, the patient is administered a premedication such as dexamethasone, oral paracetamol / acetaminophen, diphenhydramine, hydroxyzine, fexofenadine, cetirizine, ranitidine, famotidine, or other IV histamine H1 or H2 receptor antagonists. In some embodiments, the premedication is administered about one hour prior to patisiran. In some embodiments, the patient is further administered an oral daily dose of the USDA recommended daily allowance of vitamin A. In some embodiments, the patient is also administered a tetramer stabilizer such as tafamidis or diflunisal.

[0233] In some embodiments, the patient treated with the disclosed methods may be Caucasian, may reside in North America, may be 65 years of age or older, may be male, may have FAP stage I, may have FAP stage II, may have a baseline mNIS+7 score of 8-165, may have a Val30 Met TTR mutation, may have one or more TTR mutations found in Table X, may have echocardiographic evidence of cardiac amyloid involvement, and / or may have a history of prior long-term TTR tetramer stabilizer use. In some embodiments, administration of the at least one agent is performed by the patient. In other embodiments, administration of the at least one agent is performed by a medical professional.

[0234] Example 6. Stable cardiac function measured using non-invasive pressure-volume analysis with patisiran administration background Transthyretin-mediated (ATTR) amyloidosis, caused by destabilization of the transthyretin (TTR) protein, leads to the deposition of amyloid fibrils in the heart, nerves, and other organs.

[0235] Patisiran, an RNA interference (RNAi) therapeutic that inhibits hepatic synthesis of TTR, was approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis polyneuropathy based on the phase III APOLLO trial.

[0236] This post-hoc analysis uses non-invasive pressure-volume (PV) technology to further detail the effects of patisiran on left ventricular (LV) mechanics in the APOLLO trial.

[0237] method All patients enrolled in the APOLLO trial had a diagnosis of hATTR amyloidosis with polyneuropathy. Noninvasive PV loops were constructed for patients with available core laboratory echocardiograms from the APOLLO trial using Doppler estimates of LV volumes, LV pressures, and blood pressure.

[0238] End-systolic PV relationship (ESPVR) and end-diastolic PV relationship (EDPVR) were derived from previously validated techniques for each subject. The area between ESPVR and EDPVR, the isovolumic PV area indexed to LV end-diastolic pressure at 30 mmHg (PVAiso30), was used as the primary measure of LV function and tracked over time. ANCOVA was used to assess the significance of differences between treatment groups in least squares (LS) mean changes from baseline in PVAiso30 at 9 and 18 months.

[0239] result A total of 225 patients from a modified intention-to-treat (mITT) study population were included. At baseline, the mean PVAiso30 was 13,319 mmHg. *mL (a decrease of approximately 25% from normal).

[0240] At 9 months, the LS mean change in PVAiso30 was -77 mmHg with patisiran. * mL, placebo -2003mmHg * At 18 months, the LS mean change in PVAiso30 was -565 mmHg for patisiran and -570 mmHg for cerebrospinal fluid (p<0.001). * mL, placebo -2810mmHg * mL (p<0.001). The decrease in PVAiso30 was driven by a decrease in LV capacitance at both time points.

[0241] Changes in echocardiographic and pressure-volume parameters for patients in the mITT study population with baseline and available echocardiographic data are shown in Table 4. Figures 12A and 12B show graphs of the change in pressure-volume loops (Figure 12A) and isovolumic pressure-volume area (Figure 12B) at 9 months (dashed lines) compared to baseline (solid lines) and stratified by treatment group. Figures 13A and 13B show graphs of the change in pressure-volume loops (Figure 13A) and isovolumic pressure-volume area (Figure 13B) at 18 months (dashed lines) compared to baseline (solid lines) and stratified by treatment group.

[0242] These results indicate that patisiran slows the progression of LV chamber dysfunction over 18 months of treatment by preventing the decline in LV capacitance.Treatment with patisiran results in stable cardiac function in patients with hereditary transthyretin amyloidosis assessed using noninvasive pressure-volume analysis. [Table 19] [Table 20]

[0243] Table 4: IVS, mid-ventricular wall; PW, posterior wall; LVMi, left ventricular mass indexed to body surface area; RWT, relative wall thickness; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; SVi, stroke volume indexed to body surface area; LVEF, left ventricular ejection fraction; MCF, myocardial contractility; GLS, global longitudinal strain; LVEDP, estimated left ventricular end-diastolic pressure; LVESP, estimated left ventricular end-systolic pressure; Ees, end-systolic elasticity, Ea; arterial elasticity, Vo; estimated ventricular volume at 0mmHg pressure; V120; estimated left ventricular volume at 120mmHg pressure; V30; estimated left ventricular volume at 30mmHg pressure; PVA iso 30, isovolumic pressure-volume area indexed to left ventricular end-diastolic pressure of 30 mm Hg; * Changes from baseline were compared using ANCOVA as outcome variables and corresponding baseline values ​​and treatment groups as covariates.

[0244] While the present invention has been particularly shown and described with reference to preferred and various alternative embodiments, it will be understood by those skilled in the art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.

[0245] All references, issued patents, and patent applications cited within the body of this specification are hereby incorporated by reference in their entirety for all purposes.

Claims

1. A method for treating transthyretin-mediated amyloidosis (ATTR amyloidosis) in a human patient in need thereof, comprising administering to said patient a compound as described in Table 1 below. 【Table 1】 2. A method for treating a patient having a pulmonary artery disease comprising administering to said patient a patisiran pharmaceutical product having a composition per ml of patisiran pharmaceutical product as described in the above, said method resulting in improved or stabilised cardiac function, reduced progression of left ventricular chamber dysfunction and / or prevention of loss of left ventricular capacitance.

2. 2. The method of claim 1, wherein the patisiran pharmaceutical is administered at a dose of 0.3 mg siRNA per kg body weight.

3. The method of claim 1, wherein the patisiran pharmaceutical is administered intravenously once every three weeks.

4. The patisiran pharmaceutical product of claim 1, wherein the method further results in improvement or stabilization of cardiac markers and / or echocardiographic parameters.

5. The patisiran drug of claim 4, wherein the echocardiographic parameter is isovolumic pressure volume (PV) area.

6. The isovolumic PV area is indexed to a left ventricular (LV) end-diastolic pressure of 30 mmHg (PVA ｉｓｏ 30) A patisiran drug as described in claim 5.

7. The patisiran pharmaceutical product of claim 6, wherein the change in isovolumic PV area compared to a baseline determined prior to administration of the patisiran pharmaceutical product is stabilized compared to administration of a placebo.

8. PVA ｉｓｏ 30 change from baseline after 9 months of treatment is less than 1500, less than 1200, less than 1000, less than 800, less than 600, less than 500, less than 400, less than 300, less than 200, less than 150, or less than 100 mmHg ＊ The patisiran pharmaceutical product of claim 7, having a volume of less than mL.

9. PVA ｉｓｏ 30 change from baseline is less than 2500, less than 2000, less than 1500, less than 1200, less than 1000, less than 900, less than 800, less than 700, or less than 600 mmHg after 18 months of treatment. ＊ The patisiran pharmaceutical product of claim 7, having a volume of less than mL.

10. 2. The method of claim 1, wherein the patient is administered the patisiran medication for at least 12 months, 18 months, 24 months, 30 months, or 36 months.

11. The patisiran pharmaceutical product of claim 1, wherein the method further comprises administering to the patient premedication with the following: dexamethasone, oral paracetamol / acetaminophen, diphenhydramine, and ranitidine.

12. The method of claim 1, further comprising administering to the patient: a. IV dexamethasone 10 mg, or equivalent, and b. Oral paracetamol / acetaminophen 500 mg, or equivalent, and c. IV histamine H1 receptor antagonist (H1 blocker): diphenhydramine 50 mg, or equivalent, and d. IV histamine H2 receptor antagonist (H2 blocker): ranitidine 50 mg; The patisiran pharmaceutical product of claim 1, further comprising administering a premedication of

13. The patisiran pharmaceutical product of claim 11 or 12, wherein the premedication is administered about one hour prior to administration of the patisiran pharmaceutical product.

14. The patisiran pharmaceutical product of claim 1, wherein the method further comprises administering to the patient a daily oral dose of the USDA Recommended Daily Allowance of Vitamin A.

15. The patisiran pharmaceutical product of claim 1, wherein the method further comprises administering to the patient a tetramer stabilizer.

16. The patisiran pharmaceutical product of claim 15, wherein the tetramer stabilizer is tafamidis or diflunisal.

17. The patient, a. Are white, and / or b. Resides in North America; and / or c. 65 years of age or older; and / or d. Male; and / or e. Have FAP stage I, and / or f. Have FAP stage II, and / or g. has a baseline mNIS+7 score of 8-165; and / or h. has the Val30 Met TTR mutation, and / or i. Table 2 【Table 2】 and / or j. Have echocardiographic evidence of cardiac amyloid involvement; and / or k. Has a history of long-term prior use of TTR tetramer stabilizers; The patisiran drug of claim 1.

18. The patisiran pharmaceutical product of claim 1, wherein the patient has polyneuropathy and / or cardiomyopathy.

19. The patisiran pharmaceutical product described in claim 1, wherein administration of the patisiran pharmaceutical product is performed by the patient.

20. The patisiran pharmaceutical product described in claim 1, wherein administration of the patisiran pharmaceutical product is performed by a medical professional.

21. 2. The patisiran pharmaceutical product of claim 1, wherein administration is carried out over 80 minutes.

22. The patisiran pharmaceutical product of any one of claims 7 to 9 and 17, wherein the baseline is an average.

23. The patisiran pharmaceutical composition of claim 1, wherein the TTR amyloidosis is hereditary TTR amyloidosis.

Images